July 10, 2023 07:23 AM EDTUpdated 01:22 PM

Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M and $66M

Kyle LaHucik

Senior Reporter

Apogee Therapeutics and Sagimet Biosciences offered new details on their IPO plans Monday morning, saying they look to raise $228 million and $66 million in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M and $66M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Biotech VC firm outlines plans for $100M fund

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Breaking down silos with a new quantitative approach to drug development

Apogee and Sagimet’s IPO plans come in­to view, with tar­get­ed rais­es of $228M and $66M

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M and $66M